<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142215/" ref="ordinalpos=4496&amp;ncbi_uid=6530059&amp;link_uid=PMC4142215" image-link="/pmc/articles/PMC4142215/figure/F1/" class="imagepopup">Figure 1. Annotation of KEGG ERBB2 <span class="highlight" style="background-color:">signaling</span> pathways with transcriptomic data, Part A SUM190, Part B SUM149. The <span class="highlight" style="background-color:">pathway</span> was derived from http://www.genome.jp/kegg/<span class="highlight" style="background-color:">pathway</span>/hsa/hsa04012.html in January 2012.  From: Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. </a></div><br /><div class="p4l_captionBody">The RPKM values are shown as follows. Green circle: RPKM value is larger than 15; yellow circle: RPKM value is between 3 and 15; red circle: RPKM value is between 1 and 3; blue cross: transcription value is under detection limit; blue line: potential preferred signaling based on transcript levels.</div></div>